ClinicalTrials.gg
CompletedNCT06236334ELFIUpdated Nov 22, 2024

ELFI Health (e-Health for Empowerment by Lifestyle, Food Advice and Interaction)

An interventional study of ELFI lifestyle intervention in Pre-diabetes, sponsored by TNO. Completed at 1 site in Netherlands. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-11-22.

Sponsored by TNO · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
9
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Study summary

In the present study the investigators will examine whether people living with prediabetes benefit from an e-health lifestyle intervention of three months.

Read the detailed description

In the Netherlands about 1,2 million people are living with type 2 diabetes. This number increases weekly by an average of 1000 people. Besides, an equal number of people are living in a condition of prediabetes. In this precondition of type 2 diabetes, prevention is still possible for people by changing their lifestyle. Ideally, for every individual a personalised lifestyle intervention, adapted to the individual situation, biology and preferences is advised. A personalised lifestyle intervention is effective in preventing and delaying progression to type 2 diabetes. In this study, it will be investigated whether it is feasible to perform a personalised lifestyle intervention in combination with an online e-health platform. The e-Health for Empowerment by Lifestyle, Food advice and Interaction (ELFI) Health lifestyle intervention aims to improve the lifestyle of people with prediabetes to prevent them from developing type 2 diabetes.

Therefore, the primary objective is to execute a feasibility study of the ELFI Health lifestyle intervention for three months in people with prediabetes in primary care (based on HbA1c). The secondary objectives are assessing the impact of the ELFI health lifestyle intervention after three months on objective outcome parameters, including lipid profile, body composition, waist and hip circumference, blood pressure, and nutritional intake, as well as evaluating the lifestyle intervention and the online e-health platform used by participants and medical professionals.

The study is a feasibility study, studying the ability of a personalised lifestyle intervention and e-health platform to change lifestyle behaviour and decrease the risk for the development of type 2 diabetes in people with prediabetes.

The participants are newly diagnosed adults with prediabetes, aged 18-70 years. Prediabetes is defined as people with disturbed glucose values based on HbA1c levels of 39 - 53 mmol/mol (= 5.7 - 7.0%).

The intervention in this study consists of a personalised lifestyle intervention for three months. After measurements of HbA1c, blood lipids, body composition, waist and hip circumferences, blood pressure, and after assessment of food intake, a personal goal is set and participants start following the personalised lifestyle intervention. This is partly a digital intervention and partly a physical intervention (blended care). The digital part is followed via an online e-health platform, which offers different information modules. The physical part consists of different measurements of the outcome parameters and community events, where participants are in contact with their general practitioner and peers. Besides, participants have three appointments during the intervention period with a dietician to discuss their personalised program.

The main study outcome is the feasibility of the ELFI Health lifestyle intervention for three months in people with prediabetes in primary care. Key question is whether the intervention is appreciated by the subjects and working sufficiently to motivate participants in maintaining a healthier lifestyle. The feasibility will be evaluated by examination of the HbA1c level and subsequent prediabetes risk.

02

Conditions studied

  • Pre-diabetes

Keywords

  • lifestyle
  • e-health
  • behavior
03

In context

Glucose Intolerance

793 studies on the registry are indexed under Glucose Intolerance; 115 are open to participants now.

This study's enrollment of 9 is below the median of 56 across 661 interventional studies indexed under Glucose Intolerance.

Browse Glucose Intolerance studies →

Lead sponsor

TNO is the lead sponsor of 32 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy as assessed with screening questionnaire
  2. : 39 - 53 mmol/mol (= 5.7 - 7.0%)
  3. Age between 18 - 70 years
  4. Stable of 25 - 35 kg/m2
  5. signed
  6. Willing to comply with the study procedures during the study
  7. Being able to become more physically active, as assessed by the screening questionnaire (P9885 F02; in Dutch).
  8. Being digitally competent
  9. Willing to accept the use of all nameless data, including publication, and the confidential use and storage of all data for at least 15 years

Exclusion criteria

Exclusion Criteria:

  1. Being diagnosed with diabetes type 1 or 2
  2. Use of insulin, (systemic), or beta-blockers in past month
  3. Use of oral diabetes medication in past year
  4. (Having a history of a) medical condition that might significantly affect the study outcome as judged by the general practitioner and health and lifestyle questionnaire. This includes gastrointestinal dysfunction, diseases related to inflammation or allergy, or a psychiatric disorder
  5. Being abroad or on vacation for longer than a week.
  6. Alcohol consumption > 21 (women) - 28 (men) units/week
  7. Reported unexplained weight loss or gain of > 2 kg in the month prior to the pre-study screening
  8. Recent blood donation (\<1 month prior to the start of the study)
  9. Not willing to give up blood donation during the study
  10. Not willing to accept information-transfer concerning participation in the study, or information regarding his health, like laboratory results, findings at anamnesis or physical examination and eventual adverse events to and from his general practitioner.
  11. Pregnant or lactating women
  12. Involved in another Combined Lifestyle Intervention or weight loss program
  13. On GLP-1 analogues to stimulate weight loss
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
9 participants (actual)

Study arms

  • Experimental
    Lifestyle intervention

    The intervention will be a twelve week lifestyle intervention (live and online)

    Behavioral: ELFI lifestyle intervention

Interventions

  • BehavioralELFI lifestyle intervention

    A (digital) lifestyle support intervention. Based on anthropometrics, food intake and lifestyle preferences, subjects will receive behavioral lifestyle support, especially with the focus on healthy food intake.

06

What researchers measure

Primary outcomes

  1. Diabetes risk based on HbA1c level (mmol/mol)

    Change in HbA1c due to lifestyle intervention (in mmol/mol)

    Time frame: three months

Secondary outcomes

  1. Lipid profile (mmol/L)

    change in lipid profile due to lifestyle intervention (mmol/L)

    Time frame: three months

  2. body weight (kg)

    change in body weight (kg) due to lifestyle intervention

    Time frame: three months

  3. body fat % (%)

    change in body fat % (%) due to lifestyle intervention

    Time frame: three months

  4. waist circumference (cm)

    change in waist circumference (cm) due to lifestyle intervention

    Time frame: three months

  5. hip circumference (cm)

    change in hip circumference (cm) due to lifestyle intervention

    Time frame: three months

  6. Habitual food intake (frequencies, number and grams)

    Changes in habitual food intake (frequencies, number and grams)will be examined with q food intake questionnaire before, during and after the intervention intervention program

    Time frame: three months

07

Study locations

1 site
  • TNO
    Leiden, Holland 2333 BE, Netherlands
08

References and documents

Publications

  • Uusitupa M, Khan TA, Viguiliouk E, Kahleova H, Rivellese AA, Hermansen K, Pfeiffer A, Thanopoulou A, Salas-Salvado J, Schwab U, Sievenpiper JL. Prevention of Type 2 Diabetes by Lifestyle Changes: A Systematic Review and Meta-Analysis. Nutrients. 2019 Nov 1;11(11):2611. doi: 10.3390/nu11112611. PubMed 31683759 ↗
  • Galaviz KI, Weber MB, Suvada K BS, Gujral UP, Wei J, Merchant R, Dharanendra S, Haw JS, Narayan KMV, Ali MK. Interventions for Reversing Prediabetes: A Systematic Review and Meta-Analysis. Am J Prev Med. 2022 Apr;62(4):614-625. doi: 10.1016/j.amepre.2021.10.020. Epub 2022 Feb 10. PubMed 35151523 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 22, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06236334
Lead sponsor
TNO
Collaborators
Roche Diagnostics GmbH, World Data Exchange
Responsible party
Sponsor
First posted
Feb 1, 2024
Start date
Mar 25, 2024
Primary completion
Aug 8, 2024
Completion
Nov 8, 2024
Last update
Nov 22, 2024

Study contacts

Suzan Wopereis, PhD
principal investigator · TNO

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion